Search Results - "Naumann, R."

Advances in immunotherapy for cervical cancer by Wendel Naumann, R., Leath, Charles A.

“…PURPOSE OF REVIEWNovel therapies are needed for the treatment of recurrent cervical cancer. The best chemotherapy regimen to date has a response rate of 48%…”
Get full text

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial by Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J, Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L, Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N

“…Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report…”
Get full text

The SHAPE trial: is good is good enough? by Naumann, R Wendel

“…KCI Citation Count: 0…”
Get full text

Minimally Invasive Radical Hysterectomy Has Many Benefits Compared with Open Radical Hysterectomy: Will the LACC Trial Cause the Premature Demise of This Procedure? by Naumann, R. Wendel

Get full text

Re-evaluating “Success” as It Pertains to Surgical Trials by Naumann, R. Wendel

“…The objective of this article is to review the difficulties with the design and interpretation of surgical clinical trials. Few surgical procedures are…”
Get full text

The role of lymphadenectomy in endometrial cancer: Was the ASTEC trial doomed by design and are we destined to repeat that mistake? by Naumann, R. Wendel

“…Abstract Objective This study examines the design of previous and future trials of lymph node dissection in endometrial cancer. Methods Data from previous…”
Get full text

The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage by Naumann, R. Wendel, Hughes, Brittany N., Brown, Jubilee, Drury, Lane K., Herzog, Thomas J.

“…Opportunistic salpingectomy at the time of hysterectomy or as an alternative to bilateral tubal ligation may reduce the incidence of ovarian cancer, because it…”
Get full text

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer by Naumann, R. Wendel, Coleman, Robert L.

“…Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge…”
Get full text

Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology by Conrad, Lesley B, Ramirez, Pedro T, Burke, William, Naumann, R Wendel, Ring, Kari L, Munsell, Mark F, Frumovitz, Michael

“…To evaluate the current patterns of use of minimally invasive surgical procedures, including traditional, robotic-assisted, and single-port laparoscopy, by…”
Get more information

Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive? by Naumann, R. Wendel, Brown, Jubilee

“…To measure the effectiveness of ovarian cancer screening using the Risk of Ovarian Cancer Algorithm (ROCA). A Markov model was constructed based on the UK…”
Get full text

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) by Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, S W, Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J, Illerhaus, G

“…To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted…”
Get full text

Phase III trials in ovarian cancer: The evolving landscape of front line therapy by Naumann, R. Wendel, Coleman, Robert L., Brown, Jubilee, Moore, Kathleen N.

“…Ovarian cancer has a high mortality to case ratio. To improve the initial response to therapy, trials of biologic agents in combination with primary…”
Get full text

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial by Oaknin, Ana, Moore, Kathleen, Meyer, Tim, López-Picazo González, José, Devriese, Lot A, Amin, Asim, Lao, Christopher D, Boni, Valentina, Sharfman, William H, Park, Jong Chul, Tahara, Makoto, Topalian, Suzanne L, Magallanes, Manuel, Molina Alavez, Alejandro, Khan, Tariq Aziz, Copigneaux, Catherine, Lee, Michelle, Garnett-Benson, Charlie, Wang, Xuya, Naumann, R Wendel

“…In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the…”
Get full text

The Benefits of Laparoscopic Radical Hysterectomy for Cervical Cancer: Res Ipsa Loquitur? by Lovell, Daniel Y., Naumann, R. Wendel

“…Many studies have documented the peri-operative benefits of laparoscopic surgery.  Despite the objective benefits to laparoscopic surgery, quality of life…”
Get full text

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer by NAUMANN, R. Wendel, COLEMAN, Robert L, GERSH, Robert H, TENERIELLO, Michael G, HARB, Wael A, KONSTANTINOPOULOS, Panagiotis A, PENSON, Richard T, SYMANOWSKI, James T, LOVEJOY, Chandra D, LEAMON, Christopher P, MORGENSTERN, David E, MESSMANN, Richard A, BURGER, Robert A, SAUSVILLE, Edward A, KUTARSKA, Elzbieta, GHAMANDE, Sharad A, GABRAIL, Nashat Y, DEPASQUALE, Stephen E, NOWARA, Elzbieta, GILBERT, Lucy

“…Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial…”
Get full text

The Role of Colonoscopy and Radiological Procedures in the Management of Acute Lower Intestinal Bleeding by Strate, Lisa L, Naumann, Christopher R

“…There are multiple strategies for evaluating and treating lower intestinal bleeding (LIB). Colonoscopy has become the preferred initial test for most patients…”
Get full text

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer by Fu, Siqing, Corr, Bradley R, Culm-Merdek, Kerry, Mockbee, Colleen, Youssoufian, Hagop, Stagg, Robert, Naumann, R Wendel, Wenham, Robert M, Rosengarten, Rafael D, Benjamin, Laura, Hamilton, Erika Paige, Moore, Kathleen N

“…This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth…”
Get full text

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide) by Morris, R.T., Joyrich, R.N., Naumann, R.W., Shah, N.P., Maurer, A.H., Strauss, H.W., Uszler, J.M., Symanowski, J.T., Ellis, P.R., Harb, W.A.

“…This report examines 99mTc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or…”
Get full text

Workplace Harassment and Discrimination in Gynecology: Results of the AAGL Member Survey by Brown, Jubilee, Drury, Lane, Raub, Kyle, Levy, Barbara, Brantner, Paula, Krivak, Thomas C., Bradley, Linda, Naumann, R. Wendel

“…To characterize workplace and sexual harassment and discrimination among physicians in gynecology. A beta-tested Internet survey was distributed by e-mail…”
Get full text

Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis by Pothuri, Bhavana, Alvarez Secord, Angeles, Armstrong, Deborah K., Chan, John, Fader, Amanda N., Huh, Warner, Kesterson, Joshua, Liu, Joyce F., Moore, Kathleen, Westin, Shannon N., Naumann, R. Wendel

“…The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them…”
Get full text